Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab versus placebo with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy
MOH_2022-08-15_011983Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of magrolimab in acute myeloid leukemia (AML) (2 arms), sponsored by Gilead Sciences. Started Aug 2022; status: completed.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-08-15_011983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-15_011983.